Pacific Edge Limited (ASX:PEB)

Market Cap	146.36M +55.4%
Revenue (ttm)	15.99M -19.4%
Net Income	-30.29M
EPS	-0.04
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	191
Average Volume	18,883
Open	0.1500
Previous Close	0.1450
Day's Range	0.1450 - 0.1500
52-Week Range	0.0700 - 0.2200
Beta	0.74
RSI	39.52
Earnings Date	May 24, 2026

About Pacific Edge

Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the detection and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up for patients with haematuria who have a low probability of bladder cancer; and Cxbladder Monitor, a non-inva...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2001
• Employees: 114
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PEB

Financial Performance

In fiscal year 2025, Pacific Edge's revenue was 22.75 million, a decrease of -9.83% compared to the previous year's 25.23 million. Losses were -29.94 million, 1.36% more than in 2024.

Financial numbers in NZD